Header Logo

Connection

FRANK E. MOTT to Maximum Tolerated Dose

Back to Details
This is a "connection" page, showing publications FRANK E. MOTT has written about Maximum Tolerated Dose.
FRANK E. MOTT
Connection Strength
0.047
Maximum Tolerated Dose
  1. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist. 2024 Apr 04; 29(4):e514-e525.
    View in: PubMed
    Score: 0.047
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.